Wendell David Associates Inc. Has $22.01 Million Stock Holdings in AbbVie Inc. $ABBV

Wendell David Associates Inc. lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 96,321 shares of the company’s stock after selling 3,431 shares during the period. AbbVie accounts for 2.2% of Wendell David Associates Inc.’s portfolio, making the stock its 13th largest position. Wendell David Associates Inc.’s holdings in AbbVie were worth $22,008,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie during the third quarter worth $26,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at about $31,000. WestEnd Advisors LLC grew its stake in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. Finally, Caitlin John LLC acquired a new position in AbbVie in the third quarter valued at about $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Morgan Stanley boosted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Cantor Fitzgerald cut their price objective on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 8th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $252.38.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 revenue beat and companyraised full?year adjusted EPS guidance, driven by strong Skyrizi and Rinvoq sales and strength in neuroscience (Botox/Vraylar). That top?line beat and guidance lift are the main reasons the stock is trading higher today. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: AbbVie filed for FDA approval to expand Rinvoq (upadacitinib) to severe alopecia areata and reported strong Phase 3 data—successful label expansion would broaden a high?growth franchise and support longer?term revenue upside. AbbVie Submits Application to FDA for Upadacitinib
• Neutral Sentiment: AbbVie took a strategic option/warrant position with Kestrel (KRAS program) and continues external R&D partnerships (e.g., EvolveImmune milestone) — these expand oncology exposure but are longer?dated potential drivers rather than immediate EPS levers. AbbVie sinks talons into KRAS with right to buy Kestrel
• Negative Sentiment: Adjusted EPS was reported at $2.65 — while many outlets framed results as a beat on revenue and guidance, EPS compared mixedly to different consensus numbers (some providers showed a slight miss/on?par), which has created some investor push?pull and intra?day volatility. AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates
• Negative Sentiment: Erste Group slightly trimmed its FY2026 and FY2027 EPS forecasts (FY26 to $14.13 from $14.55; FY27 to $16.10 from $16.16) — modest analyst downgrades add downward pressure, though cuts are small relative to the company’s raised 2026 guidance range. Erste Group analyst note (via MarketBeat)

AbbVie Price Performance

Shares of NYSE:ABBV opened at $204.20 on Thursday. The company’s 50-day moving average price is $214.80 and its two-hundred day moving average price is $221.67. AbbVie Inc. has a one year low of $176.57 and a one year high of $244.81. The stock has a market capitalization of $361.06 billion, a PE ratio of 86.53, a price-to-earnings-growth ratio of 0.71 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, missing the consensus estimate of $3.01 by ($0.36). AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the firm earned $2.46 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, analysts anticipate that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie’s payout ratio is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.